Humira licensed for paediatric Crohn's

The licensed indications for Humira (adalimumab) have been extended to include treatment of severe active Crohn's disease in children aged 6 years and older.

In addition to its Crohn's indication (pictured), Humira is also licensed for ulcerative colitis  | SCIENCE PHOTO LIBRARY
In addition to its Crohn's indication (pictured), Humira is also licensed for ulcerative colitis | SCIENCE PHOTO LIBRARY

Humira (adalimumab) can be prescribed in children who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid and an immunomodulator, or who are intolerant to or have contraindications for such therapies.

Dosing recommendations

Children weighing less than 40kg should receive an initial dose of 40mg followed by a 20mg dose two weeks later. Dosing should then be continued at 20mg on alternate weeks, increasing to 20mg once weekly if necessary. In children weighing 40kg or more the recommended dose is 80mg initially followed by 40mg two weeks later, then 40mg every one or two weeks. Humira is given by subcutaneous injection.

View Humira record

Further information: AbbVie Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Humira now licensed for psoriasis treatment in children

Humira now licensed for psoriasis treatment in children

Humira (adalimumab) is now licensed for the treatment...

In Depth | Entyvio: gut-selective immunosuppressant for inflammatory bowel disease

In Depth | Entyvio: gut-selective immunosuppressant for inflammatory bowel disease

Takeda has launched Entyvio (vedolizumab) for the treatment...

Further licence extension for adalimumab in arthritis

Further licence extension for adalimumab in arthritis

Humira is the first biologic specifically licensed...

Humira approved for use in moderate Crohn's disease

Humira approved for use in moderate Crohn's disease

The licensed indications for Humira (adalimumab) have...

Humira: new treatment option for ulcerative colitis

Humira: new treatment option for ulcerative colitis

Humira (adalimumab) can now be prescribed for the treatment...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more